SOURCE: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc.

September 23, 2013 08:00 ET

Matinas BioPharma Announces Presentation at the 2013 Aegis Capital Healthcare Conference

TARPON SPRINGS, FL--(Marketwired - September 23, 2013) - Matinas BioPharma Holdings, Inc., an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular conditions, announced today that it will be featured as a presenting company at the 2013 Aegis Capital Healthcare Conference. The conference is being held September 25-28, 2013 in Las Vegas, Nevada.

Roelof Rongen, Matinas BioPharma's Chief Executive Officer, will provide an overview of the Company's business during the live presentation on Friday, September 27, 2013 at 2:30 p.m. ET (11:30 a.m. PT). 

About Matinas BioPharma
Matinas BioPharma Holdings, Inc. is an early stage privately-held biopharmaceutical company focused on the development of omega-3-based prescription therapeutics for the treatment of cardiovascular conditions. The Company's lead product candidate, MAT9001, is designed for treatment of severe hypertriglyceridemia (TG > 500 mg/dl) and mixed dyslipidemia (TG 200-499 mg/dl while on statin therapy). The Matinas BioPharma management team brings a cumulative multi-decade omega-3 pharmaceutical experience to the Company, providing a unique perspective and capability for the development of the next generation of omega-3-fatty acid-based pharmaceutical products.

For more information, please visit www.matinasbiopharma.com.

Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from studies and clinical trials involving MAT9001 or other product candidates. Matinas BioPharma also faces risks related to its ability to enroll patients in studies and may need to modify or delay these studies. As a result, MAT9001 may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to Matinas BioPharma and the Company assumes no obligation to update any such forward-looking statements.

Contact Information

  • Investor and Media Contact
    Jenene Thomas
    Jenene Thomas Communications, LLC
    Investor Relations and Corporate Communications Advisor
    Phone: +1 (908) 938-1475
    Email: Jthomas@matinasbiopharma.com